RxDoctor Payments Data

Jay Lonsway, DO

Urology · Holland, MINPI 1770593741

Payments from drug & device makers

$1,489in general payments, 2019–2025

Across 53 payments — averaging $28.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$483
  • Astellas Pharma US Inc$261
  • Johnson & Johnson$203
  • Boston Scientific$159
  • AbbVie$136
  • Medtronic$89
  • plus $159 from 5 others

What the payments were for

  • Food & beverage$1,00768%
  • Education$48232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast7$483
Astellas Pharma US Inc16$261
Johnson & Johnson4$203
Boston Scientific4$159
AbbVie(2 entities)9$136
Medtronic(2 entities)4$89
180 Medical, Inc.3$51
AstraZeneca2$47
Pfizer2$33
Myovant Sciences Inc.1$14
Rochester Medical Corporation1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,489 in reported general payments places this provider in the 40th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$57,995
Medicare patients
299
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron115$73,913
Tamsulosin Hcl442$6,999
Tolterodine Tartrate ErTolterodine Tartrate120$6,858
Trospium Chloride ErTrospium Chloride25$3,961
Methenamine Hippurate38$3,560
Trimethoprim59$3,305
Finasteride229$2,957
Solifenacin Succinate61$1,764
Testosterone12$1,342
Alfuzosin Hcl ErAlfuzosin Hcl60$1,211
Testosterone Cypionate34$1,017
Oxybutynin Chloride78$991
Oxybutynin Chloride ErOxybutynin Chloride34$549
CefuroximeCefuroxime Axetil26$423
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$261$73,913115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 400 urology providers in Michigan.

Other urology in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →